Q2 EPS Estimates for Globus Medical Cut by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Zacks Research dropped their Q2 2025 EPS estimates for Globus Medical in a report released on Thursday, May 29th. Zacks Research analyst R. Department now forecasts that the medical device company will earn $0.79 per share for the quarter, down from their prior forecast of $0.85. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s FY2025 earnings at $3.17 EPS, Q1 2026 earnings at $0.84 EPS, FY2026 earnings at $3.70 EPS, Q1 2027 earnings at $0.88 EPS and FY2027 earnings at $4.19 EPS.

A number of other analysts have also recently issued reports on the stock. Stifel Nicolaus increased their price objective on shares of Globus Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Truist Financial dropped their target price on shares of Globus Medical from $80.00 to $68.00 and set a “hold” rating for the company in a research report on Monday, May 12th. JMP Securities reiterated a “market perform” rating on shares of Globus Medical in a research report on Tuesday, May 27th. Wells Fargo & Company reduced their target price on shares of Globus Medical from $95.00 to $93.00 and set an “overweight” rating on the stock in a research note on Friday, February 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a research note on Tuesday, March 18th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Globus Medical Price Performance

Shares of NYSE GMED opened at $59.78 on Monday. The firm has a fifty day moving average price of $67.21 and a 200-day moving average price of $77.70. The stock has a market cap of $8.09 billion, a PE ratio of 79.71, a price-to-earnings-growth ratio of 1.61 and a beta of 1.32. Globus Medical has a 1 year low of $54.48 and a 1 year high of $94.93.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 8th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.06). The firm had revenue of $598.12 million during the quarter, compared to analysts’ expectations of $629.74 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company earned $0.72 earnings per share.

Globus Medical announced that its board has approved a share buyback plan on Thursday, May 15th that permits the company to buyback $500.00 million in shares. This buyback authorization permits the medical device company to reacquire up to 6.3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Globus Medical

Several hedge funds have recently modified their holdings of GMED. SBI Securities Co. Ltd. purchased a new stake in shares of Globus Medical in the 4th quarter worth approximately $27,000. Farther Finance Advisors LLC lifted its position in Globus Medical by 145.5% during the first quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 240 shares during the last quarter. Larson Financial Group LLC lifted its position in Globus Medical by 1,007.7% during the first quarter. Larson Financial Group LLC now owns 432 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 393 shares during the last quarter. Parallel Advisors LLC lifted its position in Globus Medical by 62.1% during the first quarter. Parallel Advisors LLC now owns 504 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 193 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Globus Medical by 932.1% during the first quarter. Versant Capital Management Inc now owns 547 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 494 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.